GlassScriptPhysician profile
Gary M Horbar
NPI 1851442198
$5,345.75
in general payments reported to CMS, 2019-2025
34 companies · $736 in 2025
The $736 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $660 · 2021: $905 · 2022: $648 · 2023: $845 · 2024: $792 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,372.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,289.14 | 2019-2025 | |
| Pfizer INC. | $545.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $448.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $415.50 | 2020-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $364.11 | 2019-2024 | Breztri, Farxiga |
| Almatica Pharma LLC | $246.92 | 2021-2025 | Loreev Xr, Gralise, Sertraline Hcl |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.32 | 2019-2025 | Xifaxan |
| Amneal Pharmaceuticals LLC | $196.66 | 2020-2024 | Unithroid |
| Kowa Pharmaceuticals America, INC. | $184.24 | 2019-2023 | Livalo, Seglentis |
| Allergan, INC. | $163.03 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $138.07 | 2022-2025 | Quviviq, Quviviq |
| Lilly USA, LLC | $130.49 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $106.78 | 2019-2024 | Camzyos, Eliquis |
| Amgen INC. | $98.78 | 2019-2023 | Otezla, Repatha |
| Exact Sciences Corporation | $95.19 | 2023-2025 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $90.96 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $83.29 | 2021-2024 | Xarelto |
| Astellas Pharma US INC | $70.95 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $50.24 | 2023-2024 | |
| Eisai INC. | $47.70 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.77 | 2019 | |
| Phathom Pharmaceuticals, INC. | $41.31 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $41.29 | 2025 | |
| Philips North America LLC | $37.94 | 2022 | |
| Shire North American Group INC | $22.63 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $22.03 | 2019 | |
| Althera Pharmaceuticals LLC | $21.52 | 2021 | |
| Bavarian Nordic A/S | $21.49 | 2025 | Vivotif |
| Ibsa Pharma INC. | $21.42 | 2020 | |
| Sanofi Pasteur INC. | $20.54 | 2019 | |
| Merck Sharp & Dohme LLC | $19.46 | 2022 | |
| Sumitomo Pharma America, INC. | $18.68 | 2025 | Gemtesa |
| Heartflow, INC. | $18.19 | 2024 | |
| Genentech USA, INC. | $14.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Horbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.